

Foreword

It has been 20 years since the first issue of AIDS reviews was published. During these two decades, the journal has reached up to be one of the most widely read and cited scientific publications in the field of HIV/AIDS, with a rampant impact factor of 3.2.

The steadily advent of more potent and safer antiretroviral therapies has changed the AIDS scenario, an originally deadly illness. Although HIV still cannot be eliminated from carriers, the life expectancy of infected persons under those treatments is approaching that of the general population. Not surprisingly new issues have arisen, including discussions on transmission and prevention, aging and comorbidities, cancer, immune and gene therapy, psychological, and ethical issues.

Alongside, other infections have emerged (i.e., Ebola, Zika, and MDR bacteria) that somewhat are replacing HIV in challenging our ability to fight back with protection strategies, vaccines, or antimicrobials. Re-visiting this new scenario for HIV/AIDS, we would like to invite all researchers and experts in the field to consider further contributions to AIDS Reviews, expanding the topics classically addressed, and covering a much broader list of than clinical and basic science issues that have been predominantly the focus to date.

We want to promote more publications in the journal that addresses epidemiological and public health issues, psychological aspects, ethical controversies, legal challenges, as well as clinically-related medical conditions, including other viral and non-viral illnesses. For this purpose, we have renovated our editorial board, involving a wider expertise list. We would like to thank all that have been members to date and acknowledge the wonderful contribution of a few that already passed away.

Vicente Soriano
Editor-in-Chief